The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...

Dear Dr. Roach: I have suffered from asthma and nasal polyps for more than 20 years. The asthma is controlled, and I mention it only because it might have some connection with my polyps. The polyps ...

Subjective — but not objective — olfactory improvements in patients who underwent endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps were maintained up to 6 months after surgery, ...

Patients with chronic rhinosinusitis with nasal polyps were found to benefit more from the combination of endoscopic sinus surgery plus medical therapy vs medical therapy alone, although the minimal ...

Reduced health-related quality of life was identified in patients with chronic rhinosinusitis with nasal polyps compared with the general population—regardless of previous sinus surgery or presence of ...

Please provide your email address to receive an email when new articles are posted on . Wenyi Chen, of the department of otolaryngology-head and neck surgery at Third Affiliated Hospital of Sun ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients with severe chronic rhinosinusitis with nasal polyps who received mepolizumab ...

The authors utilized medical and pharmacy claims obtained from the Optum Clinformatics Data Mart Database. Among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), younger age, elevated ...

PHOENIX – Patients who have nasal polyps appeared to get symptom relief when treated with omalizumab (Xolair) regardless of comorbid asthma, according to a post-hoc trial analysis. All patients taking ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...